{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:29:09Z","timestamp":1787023749380,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10067-026-08251-3","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:51:05Z","timestamp":1782211865000},"page":"4813-4822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world evidence on JAK inhibitors in rheumatology practice: comparative safety, efficacy, and outcomes between JAK inhibitors"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4537-894X","authenticated-orcid":false,"given":"Rabia","family":"Deniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6571-7860","authenticated-orcid":false,"given":"Ay\u015fenur","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-2532","authenticated-orcid":false,"given":"Ay\u015fe Elif","family":"Boncukcuo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1348-4118","authenticated-orcid":false,"given":"Erdem","family":"Bekta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3842-6181","authenticated-orcid":false,"given":"Rumeysa Mirza","family":"Alt\u0131nta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6535-5692","authenticated-orcid":false,"given":"Hazal Ceylan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6231-9785","authenticated-orcid":false,"given":"K\u00fcbra","family":"U\u011fur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-1198","authenticated-orcid":false,"given":"G\u00fcl G\u00fczelant","family":"\u00d6zk\u00f6se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0013-2076","authenticated-orcid":false,"given":"K\u00fcbra","family":"Kalkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-2991","authenticated-orcid":false,"given":"Cemal","family":"Bes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"7","key":"8251_CR1","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60(7):1895\u20131905","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8251_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2177\/jsci.32.85","volume":"32","author":"K Yamaoka","year":"2009","unstructured":"Yamaoka K, Tanaka Y (2009) Jak inhibitor; possibility and mechanism as a new disease modifying anti-rheumatic drug. Nihon Rinsho Meneki Gakkai Kaishi 32(2):85\u201391","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"7","key":"8251_CR3","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW et al (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186(7):4234\u20134243","journal-title":"J Immunol"},{"issue":"2","key":"8251_CR4","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME et al (2016) The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34(2):318\u2013328","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"8251_CR5","doi-asserted-by":"publisher","first-page":"688","DOI":"10.25259\/IJDVL_8_2023","volume":"89","author":"SP Raychaudhuri","year":"2023","unstructured":"Raychaudhuri SP, Raychaudhuri SK (2023) JAK inhibitor: introduction. Indian J Dermatol Venereol Leprol 89(5):688\u2013690","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"8251_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P (2024) Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci 17(1):e13688","journal-title":"Clin Transl Sci"},{"issue":"11","key":"8251_CR7","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/1060028013512790","volume":"47","author":"D Vyas","year":"2013","unstructured":"Vyas D, O\u2019Dell KM, Bandy JL, Boyce EG (2013) Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 47(11):1524\u20131531","journal-title":"Ann Pharmacother"},{"issue":"3","key":"8251_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10165-012-0799-2","volume":"23","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y, Yamaoka K (2013) JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol 23(3):415\u2013424","journal-title":"Mod Rheumatol"},{"issue":"10","key":"8251_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1358\/dot.2016.52.10.2525742","volume":"52","author":"J Gras","year":"2016","unstructured":"Gras J (2016) Baricitinib: JAK inhibition for rheumatoid arthritis. Drugs Today (Barc) 52(10):543\u2013550","journal-title":"Drugs Today (Barc)"},{"issue":"18","key":"8251_CR10","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S (2017) Tofacitinib: a review in rheumatoid arthritis. Drugs 77(18):1987\u20132001","journal-title":"Drugs"},{"issue":"16","key":"8251_CR11","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s40265-019-01211-z","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S, Keam SJ (2019) Upadacitinib: first approval. Drugs 79(16):1819\u20131828","journal-title":"Drugs"},{"issue":"1","key":"8251_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/1744666X.2019.1544892","volume":"15","author":"L Serhal","year":"2019","unstructured":"Serhal L, Edwards CJ (2019) Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 15(1):13\u201325","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"8251_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00296-020-04767-2","volume":"41","author":"A Kyriakou","year":"2021","unstructured":"Kyriakou A, Parperis K, Nikiphorou E, Psarelis S (2021) Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review. Rheumatol Int 41(3):671\u2013675","journal-title":"Rheumatol Int"},{"key":"8251_CR14","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2022-11-6","author":"D Fonseca","year":"2023","unstructured":"Fonseca D, Nogueira M, Torres T (2023) Upadacitinib for the treatment of psoriatic arthritis. Drugs Context. https:\/\/doi.org\/10.7573\/dic.2022-11-6","journal-title":"Drugs Context"},{"key":"8251_CR15","doi-asserted-by":"publisher","DOI":"10.25259\/ijdvl_14_2024","author":"T Wang","year":"2024","unstructured":"Wang T, Wu W, Zhang X, Gan B, Zhou Y, Cheng X (2024) Tofacitinib treatment for plaque psoriasis and psoriatic arthritis: a meta-analysis of randomised controlled trials. Indian J Dermatol Venereol Leprol. https:\/\/doi.org\/10.25259\/ijdvl_14_2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"8251_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A et al (2023) Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002735","journal-title":"RMD Open"},{"issue":"1","key":"8251_CR17","doi-asserted-by":"publisher","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L et al (2019) Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open 5(1):e000808","journal-title":"RMD Open"},{"key":"8251_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001042","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, de Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T et al (2020) Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2019-001042","journal-title":"RMD Open"},{"issue":"10139","key":"8251_CR19","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y et al (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391(10139):2513\u20132524","journal-title":"Lancet"},{"issue":"10214","key":"8251_CR20","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394(10214):2108\u20132117","journal-title":"Lancet"},{"issue":"1","key":"8251_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K et al (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21(1):89","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"8251_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","volume":"7","author":"P Nash","year":"2020","unstructured":"Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA et al (2020) Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label. Long-Term Ext Study Rheumatol Ther 7(3):553\u2013580","journal-title":"Long-Term Ext Study Rheumatol Ther"},{"issue":"3","key":"8251_CR23","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L et al (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80(3):304\u2013311","journal-title":"Ann Rheum Dis"},{"issue":"10349","key":"8251_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH et al (2022) Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400(10349):369\u2013379","journal-title":"Lancet"},{"issue":"2","key":"8251_CR25","doi-asserted-by":"publisher","first-page":"e000308","DOI":"10.1136\/rmdopen-2016-000308","volume":"2","author":"V Strand","year":"2016","unstructured":"Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH et al (2016) Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open 2(2):e000308","journal-title":"RMD Open"},{"issue":"7","key":"8251_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306714","volume":"19","author":"K Saito","year":"2024","unstructured":"Saito K, Yoshida S, Ebina H, Miyata M, Suzuki E, Kanno T et al (2024) Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis. PLoS ONE 19(7):e0306714","journal-title":"PLoS ONE"},{"issue":"11","key":"8251_CR27","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1007\/s10067-024-07117-w","volume":"43","author":"S Hayashi","year":"2024","unstructured":"Hayashi S, Nakano N, Tsubosaka M, Kamenaga T, Kuroda Y, Matsumoto T et al (2024) Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis. Clin Rheumatol 43(11):3285\u20133292","journal-title":"Clin Rheumatol"},{"issue":"2","key":"8251_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/rheumatology\/keae081","volume":"64","author":"S Jinno","year":"2025","unstructured":"Jinno S, Onishi A, Hattori S, Dubreuil M, Ueda Y, Nishimura K et al (2025) Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study. Rheumatology (Oxford) 64(2):509\u2013516","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"8251_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/14397595.2018.1553489","volume":"29","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Yamanaka H, Yamaoka K, Arai S, Toyoizumi S, DeMasi R et al (2019) Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post hoc analysis of clinical trial data. Mod Rheumatol 29(5):756\u2013766","journal-title":"Mod Rheumatol"},{"key":"8251_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123494","author":"D Donzella","year":"2024","unstructured":"Donzella D, Bellis E, Crepaldi G, Data V, Gatto M, Lomater C et al (2024) The retention rate and safety of JAK inhibitors in rheumatoid arthritis: real word data from a monocentric cohort. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13123494","journal-title":"J Clin Med"},{"issue":"6","key":"8251_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.5114\/reum\/175626","volume":"61","author":"A Felis-Giemza","year":"2023","unstructured":"Felis-Giemza A, Moskal M, Proc K, Guzera Z, Stajszczyk M, Palej K et al (2023) Multicenter evaluation of tofacitinib retention and safety in rheumatoid arthritis - why cardiovascular risk factors do not equate to overt risk. Reumatologia 61(6):414\u2013423","journal-title":"Reumatologia"},{"issue":"10","key":"8251_CR32","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/art.42250","volume":"74","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC (2022) Tofacitinib and risk of malignancy: results from the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) study. Arthritis Rheum 74(10):1648\u20131659","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8251_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ (2022) Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 81(6):798\u2013804","journal-title":"Ann Rheum Dis"},{"key":"8251_CR34","doi-asserted-by":"publisher","unstructured":"(2022) EMA recommendations for reducing risk of serious JAK inhibitor AEs. Reactions Weekly 1931, 2. https:\/\/doi.org\/10.1007\/s40278-022-26799-7","DOI":"10.1007\/s40278-022-26799-7"},{"issue":"4","key":"8251_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"key":"8251_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19895492","volume":"11","author":"W Xie","year":"2019","unstructured":"Xie W, Xiao S, Huang Y, Sun X, Zhang Z (2019) Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis 11:1759720X19895492","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"8251_CR37","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.semarthrit.2020.08.007","volume":"50","author":"W Xie","year":"2020","unstructured":"Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z (2020) Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. Semin Arthritis Rheum 50(5):930\u2013937","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08251-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:17:11Z","timestamp":1787023031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08251-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8251"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08251-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Research Ethics Committee (Project number\/date 09.2025\u201325-0260) and all patients gave a written informed consent for both procedures and publish of medical records.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}